Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
Tao Jiang, Meng Qiao, Chao Zhao, et al.
Cancer Immunology Immunotherapy (2018) Vol. 67, Iss. 5, pp. 713-727
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel, Diego Chowell, Timothy A. Chan
Nature reviews. Cancer (2019) Vol. 19, Iss. 3, pp. 133-150
Open Access | Times Cited: 1936
Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies
Meghan A. Cupp, Margarita Cariolou, Ioanna Tzoulaki, et al.
BMC Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 421
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
Tadaaki Yamada, Soichi Hirai, Yuki Katayama, et al.
Cancer Medicine (2019) Vol. 8, Iss. 4, pp. 1521-1529
Open Access | Times Cited: 93
Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors
Tao Jiang, Yuchen Bai, Fei Zhou, et al.
Lung Cancer (2019) Vol. 130, pp. 76-83
Closed Access | Times Cited: 88
Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis
Zimu Wang, Ping Zhan, Yanling Lv, et al.
Translational Lung Cancer Research (2019) Vol. 8, Iss. 3, pp. 214-226
Open Access | Times Cited: 76
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis
Bao‐Wen Tian, Yafei Yang, Chuncheng Yang, et al.
Immunotherapy (2022) Vol. 14, Iss. 18, pp. 1481-1496
Closed Access | Times Cited: 63
Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives
Ying Yang, Hongyang Liu, Youming Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 3
Open Access | Times Cited: 34
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
Arsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Cancers (2019) Vol. 11, Iss. 12, pp. 1954-1954
Open Access | Times Cited: 69
Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Donglai Chen, Yiming Mao, Junmiao Wen, et al.
The Annals of Thoracic Surgery (2019) Vol. 108, Iss. 3, pp. 945-954
Open Access | Times Cited: 67
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
Dedong Cao, Huilin Xu, Ximing Xu, et al.
OncoImmunology (2018) Vol. 7, Iss. 11
Open Access | Times Cited: 64
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy
Arsela Prelaj, Sara Elena Rebuzzi, Pamela Pizzutilo, et al.
Clinical Lung Cancer (2020) Vol. 21, Iss. 4, pp. 365-377.e5
Closed Access | Times Cited: 62
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
Miren Zuazo, Hugo Arasanz, Ana Bocanegra, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 62
Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
Yuki Katayama, Takayuki Shimamoto, Tadaaki Yamada, et al.
Journal of Clinical Medicine (2019) Vol. 9, Iss. 1, pp. 102-102
Open Access | Times Cited: 60
Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis
Yuan Shao, Bo Wu, Jia Wei, et al.
BMC Urology (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 60
Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Xiuqiong Chen, Fanqiao Meng, Richeng Jiang
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 46
Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Liwei Ni, Jing Huang, Jiyuan Ding, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 27
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis
Silvio Matsas, Pedro Nazareth Aguiar, Auro del Giglio
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 1, pp. 33-51
Open Access | Times Cited: 5
Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis
Jialin Su, Li Yu-ning, Shuhua Tan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody
Mehmet Akce, Yuan Liu, Katerina Zakka, et al.
American Journal of Clinical Oncology (2020) Vol. 44, Iss. 2, pp. 74-81
Closed Access | Times Cited: 47
Novel Biomarkers for Personalized Cancer Immunotherapy
Yoshitaro Shindo, Shoichi Hazama, Ryouichi Tsunedomi, et al.
Cancers (2019) Vol. 11, Iss. 9, pp. 1223-1223
Open Access | Times Cited: 42
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort
K. G. Mitchell, Lixia Diao, Tatiana V. Karpinets, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000405-e000405
Open Access | Times Cited: 42
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
Byung Woog Kang, Ian Chau
ESMO Open (2020) Vol. 5, Iss. 4, pp. e000791-e000791
Open Access | Times Cited: 39
Distribution and reference interval establishment of neutral‐to‐lymphocyte ratio (NLR), lymphocyte‐to‐monocyte ratio (LMR), and platelet‐to‐lymphocyte ratio (PLR) in Chinese healthy adults
Junjun Wang, Fan Zhang, Feng Jiang, et al.
Journal of Clinical Laboratory Analysis (2021) Vol. 35, Iss. 9
Open Access | Times Cited: 38
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
Monika Pradhan, Mathieu Chocry, Don L. Gibbons, et al.
Translational Lung Cancer Research (2021) Vol. 10, Iss. 1, pp. 590-606
Open Access | Times Cited: 33
Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Zhibo Zhang, Yuan Fang, Runzhe Chen, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top